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Background. Proliferative verrucous leukoplakia (PVL) is a disease of extensive or 
multifocal verrucous-like lesions that has a high risk of recurrence and malignant 
transformation into a carcinoma. Verrucous hyperplasia (VH) is the histopathological finding 
most likely representing part of the PVL diagnosis. The objective of the present study was to 
update information on PVL and VH and critically evaluate the current diagnostic procedure of 
PVL. 
Methods. A literature search on PubMed with terms covering PVL and VH was performed to 
identify papers published between the years 2000-2013. For comparison, the referrals of 
patients diagnosed with VH at our Department of Oral Pathology covering the same time 
period were evaluated. 
Results. Fifty-four papers (1236 patients) fulfilled the inclusion criteria. At our department, 
29 patients with VH were identified. In the literature, PVL was more common in females, on 
gingiva and with no history of tobacco use, contradictory to VH. In comparison, VH of our 
departmental patients was detected most commonly on the tongue and had a female 
predilection. Of the patients diagnosed with PVL, 47% developed a carcinoma. Only 5% and 
3% of the patients with VH from the literature and from our department developed carcinoma. 
Conclusion. PVL is its own disease entity while VH is a histologic diagnosis. As PVL is 
clinically verrucous, this feature should also be identified by histology. Thus, we now suggest 
that the PVL criteria should be modified as follows: a biopsy has confirmed the presence of 
VH. This modification would improve the diagnostics of PVL. 
  
INTRODUCTION 
In 1985 Hansen et al. described proliferative verrucous leukoplakia (PVL) as a long-term 
progressive condition, which develops initially as a white plaque of hyperkeratosis that 
eventually becomes a multifocal disease (1). Since then several improvements of the 
classification have been suggested. In 2010 Cerero-Lapiedra et al. proposed a new 
classification using a set of 6 major and 4 minor criteria (2). One of the six major criteria is 
the histology of the lesion including the following categories as follows: simple epithelial 
hyperkeratosis to verrucous hyperplasia (VH), verrucous carcinoma (VC), in situ carcinoma, 
or squamous cell carcinoma (SCC) (2). In 2013 Carrard et al. suggested simplifying Cerero-
Lapiedra’s classification by omitting the major and minor criteria in their modified 
classification: the diagnosis of PVL requires the involvement of the lesions in more than two 
oral subsites, a total added size of the leukoplakic areas of at least 3 cm, and a well-
documented period of at least five years of disease evolution being characterized by spreading 
and the occurrence of one or more recurrences in a previously treated area (3). The temporal 
clinical evolution of PVL has been proposed to follow four stages according to Gillenwater et 
al. (2013): 1) one or more early focal presentations on the oral mucosa; 2) enlargement and 
spread over time (geographic expansion); 3) development of a verrucous appearance; 4) 
development of oral SCC (4). 
PVL often resists attempts at therapy and has a high rate of recurrence and malignancy to VC 
and to invasive SCC (4,5,6,7,8). Because of the aggressiveness of PVL toward malignancy, 
early detection and careful follow-up of the lesion is essential. However, early detection is not 
straightforward. Even though PVL is a distinct clinical diagnosis, it is at the same time an 
elusive lesion. It is in fact impossible to distinguish the early presentation of PVL from other 
leukoplakias, especially the more conventional multifocal leukoplakia, either grossly or 
microscopically. Therefore the diagnosis of PVL can only be made through the careful 
observation of the temporal clinicopathologic evolution of the lesion. (4,9) 
An additional difficulty with the diagnosis of PVL is that it is a clinical diagnosis that 
encompasses a spectrum of different clinical and histopathological stages. The histology of 
PVL is varied and the spectrum of PVL encompasses stages beginning from benign 
hyperplasia to VH followed by VC (1,2,4). These verrucous lesions are in themselves 
diagnostically challenging and the terminology is confusing. For example VH and VC can be 
impossible to distinguish from each other clinically and it is also challenging histologically 
(10). VH is a histological term that describes an exophytic overgrowth of well-differentiated 
keratinized epithelium that is similar to VC but without the destructive, pushing border at its 
interface with the underlying connective tissue (11). Areas of VH may be encountered in 
association with VC, SCC or PVL (11). 
The present study had two aims. First, to review all published cases including also case 
reports on PVL or VH to enlighten their most characteristic features and similarities. So far, 
systematic reviews have been done either on PVL or VH, separately. Also case reports have 
been mostly excluded in earlier reviews (5,6,8). Second, to evaluate single cases diagnosed 
with VH from the files of the Department of Oral Pathology, University of Turku, Turku, 
Finland, most likely representing the biopsy samples derived from PVL patients. 
 
  
MATERIAL AND METHODS 
Literature review. A PubMed-search was conducted using the following terms: proliferative 
verrucous leukoplakia, verrucous hyperplasia, verrucous dysplasia and verrucous papillary 
lesions. The papers on PVL and VH published in the year 2000 onwards until December 2013 
were included. Additional papers were identified by reviewing the reference lists of the 
included papers. The inclusion criterion of the papers was that at least one record on the PVL 
or VH patient existed (e.g. site of lesion or follow-up data). Exclusion criteria were the 
following: studies not found through PubMed, studies in a language other than English, and 
studies not peer reviewed. Table 1 shows the characteristics of the patients and the lesions.  
When summarizing the data from the different articles, the following information was given. 
When possible, the site of the lesions was reported at the beginning of follow-up. When 
reporting malignant transformation, if a patient had both VC and SCC, only SCC was noted. 
In addition, information on malignant transformation included both data on malignant 
transformation at the beginning, during and/or at the end of follow-up. The following studies 
included patients with malignancy already at the base line: 19, 20, 27, 28, 29, 30, 32, 38. 
The Turku patients. A single institute material of patients with the histological diagnosis of 
VH during the years 2000-2013, most likely representing the patients with PVL, was 
collected at the Department of Oral Pathology, Institute of Dentistry, University of Turku, 
Turku, Finland, and referred to here as the Turku patients. The exclusion criteria were any 
previous or current VC or SCC in the oral cavity. The clinical information was collected from 
the pathologic anatomical diagnoses (PAD) without the information to allow the identification 
of the person. Therefore there was no need for ethical approval from our institute. Similarly, 
the follow-up after the VH diagnosis was performed as a search from the institute PAD 
referrals database to see if the patient had any additional PAD-diagnosis from a later date 
until the end of October 2014 (minimum of 10 months of follow-up). 
  
RESULTS 
Literature review: PVL. The PubMed-search on PVL resulted in 32 papers that fulfilled the 
inclusion criteria as outlined in the materials and methods (Table 1). Forty-seven percent of 
the papers were case reports with only one patient. The number of the patients varied from 3 
to 58 patients in the rest of the papers. 
Totally, 388 PVL patients were identified. The patients’ characteristics together with their 
PVL data were summarized in Table 3. The female to male ratio was 2.2:1. The mean age of 
the patients was 64 years with a range of 40–84 years. Data on smoking status was available 
in 75% (292/388) of the patients. Of them 30% (88/292) were smokers or tobacco chewers. 
Information on malignant transformation of PVL was given for 94% (366/388) patients: 47% 
(173/366) of them were reported to have lesions that progressed either to VC, carcinoma in 
situ (CIS) or SCC. 
The lesions were extensive or multifocal by their nature, and the site of the lesions was given 
for 77% (300/388) of the patients. There was no specific oral site for PVL. The localization in 
decreasing order was as follows: the gingiva (59%), the buccal mucosa (47%), the tongue 
(44%), the palate (31%), the alveolar crest (21%), the lip (9%) and the oral floor (8%). The 
site of the lesions was missing in 88 patients (23%). 
Literature review: VH. Twenty-one papers on VH patients were included (Table 1). None of 
the papers were single case reports. Totally 848 patients with VH were identified in these 
papers. The number of patients per paper ranged from 5 to 324 with a mean of 44 patients. 
Some of the papers mentioned that individual patients were reported in several papers (20, 21, 
22, 23). When possible, the data of these patients was included only once when that data was 
summarized in the present study (Table 3).  
The female to male ratio was 1:3.8. The age of the patients ranged from 46 years to 62 years 
with a mean age of 54 years. Data on smoking status was available in 78% (663/848) of the 
patients and 83% (552/663) of them were reported to smoke or chew tobacco. Information on 
malignant transformation of VH was given for 62% (525/848): only 5% (25/525) of the VH 
progressed to VC or SCC with a range of 0–20% in the individual papers. 
The location of the lesions was given for 61% (519/848) of the patients. The vast majority of 
the VH cases were seen on the buccal mucosa (51%) followed by the gingiva (10%), the 
tongue (13%), the lip (12%), the palate (7%), the floor of the mouth (5%), and the alveolar 
crest (0.5%).  
Combined PVL + VH literature review. When combining the separately described data on 
PVL and VH, there were altogether 1236 patients and the female to male ratio was 1:1.3. 
Altogether, 67 % (640/955) were reported as tobacco users and malignant transformation of 
the lesions was reported in 22% (196/1891). 
Information on the site of the lesions was given for 59% (730/1236) of the patients. The main 
sites were the buccal mucosa (50%), the gingiva (31%) and the tongue (26%) followed by the 
palate (17%), the lip (11%), the alveolar crest (9%) and the floor of the mouth (6%). 
The Turku patients. Totally, 29 patients diagnosed with VH were identified at the 
Department of Oral Pathology, Turku, Finland during the years 2000-2013 (Table 2, 3). The 
female to male ratio was 1.4:1. The age of the patients ranged from 11 years to 87 years and 
the mean age was 59 years. In only 8 cases out of 29, the information of smoking was 
included in the PAD referral letter and 6 of them were reported to smoke or chew tobacco. 
According to the PAD referrals to our institute between 2000-2014, only one VH lesion 
progressed to VC after 27 months follow-up resulting in a malignancy rate of 3% in the whole 
group of 29 patients (Table 2, ID 14). The site of the lesions in the declining order was as 
follows: the tongue (48%), the buccal mucosa (34%), the alveolar crest (24%), the lip (17%), 
the palate (10%), the floor of mouth (10%), and the gingiva (7%). 
Comparison of the literature review and the Turku patients’ material. The Turku VH 
cases were both similar and different from the PVL and VH cases presented in the literature in 
regards to gender distribution, site of lesions and malignant transformation. The Turku 
patients with VH showed a predilection for females, which was similar to the PVL cases from 
the literature but not to the VH patients from the literature. The tongue was the most affected 
site of the Turku VH patients as compared to the gingiva and the buccal mucosa in the PVL 
and VH patients derived from the literature, respectively. However, the buccal mucosa was 
the second most affected site for the Turku VH patients, too. The most obvious difference 
between the Turku VH patients and those described in the literature was the rate of malignant 
transformation; only one of our departmental patients was diagnosed with VC. 
  
DISCUSSION 
VH can be the histological diagnosis of a biopsy sample from a PVL lesion although WHO 
classifies them all as PVL (65). According to the present study and systematic review of the 
literature, VH and PVL have their own distinct features 1) PVL is more likely to affect 
women than men whereas VH is more likely in men than in women. 2) Tobacco use is 
common in VH patients as 83% had a history of using tobacco products while only 30% of 
PVL patients had a history of tobacco use. 3) PVL has a high rate of malignant transformation 
as 47% of the patients developed a VC or SCC. VH presented with a low rate of malignant 
transformation as only 5 % of the lesions progressed to VC or SCC. This progression rate is 
similar to that found in leukoplakias in general. Approximately 0.13-17.5% of leukoplakias 
progress to malignancy during ten years of follow-up (66). 
The number of patients in the individual papers was not an inclusion criterion for the present 
study and almost half of the papers on PVL were actually case reports with only one case. 
More of the reported cases were covered when including also these case reports, unlike a 
recent review where only papers with 10 or more cases were included (8). Case studies can, 
however, bias the data as they usually describe clinically challenging cases and cases with 
malignant transformation. On the other hand, they can present the whole clinical spectrum of 
the disease. Only data since the year 2000 was included to present cases that are diagnosed in 
a similar way according to the criteria of these two disease entities and treated accordingly. 
In the present study, a clear predilection for PVL in women was shown (2.4:1) as reported 
also previously (4,5,6,8). Interestingly, a similar predilection in women was found also in the 
Turku patients diagnosed with VH, contradictory to that found in the VH patients from the 
literature. One explanation may be that the VH patients from the literature were more often 
smokers and smoking is more prevalent in men. 
In the present study, the majority of the PVL and VH patients from the literature had lesions 
on the gingiva and the buccal mucosa respectively, while the Turku patients had their VH 
lesions most frequently on the tongue. A few previous reviews have shown that the buccal 
mucosa and the tongue are the most affected sites for PVL (4,6). This difference between the 
reviews in the most affected site for PVL may be because of the different time periods, the 
literature review in the present study focusing on the most recent papers starting from the year 
2000 onward while the previous reviews included papers before the year 2000. However, the 
recent systematic review from Pentenero et al. found that 62.7% of the cases affect the 
gingiva, which is similar with the finding in the present study (59%) (8). 
The present study showed that 47% of PVLs from the literature progressed to carcinoma. This 
is less than reported by Cabay et al. who found that 74% of the PVL progressed to carcinoma 
(6). Pentenero et al. who also included older papers than in the present study but only those 
with 10 or more patients, reported progression to malignancy in 60.7% of the PVL during 7.4-
year follow-up (8). This indicates that reviews like ours including also case reports do not 
present only the cases with worse prognosis. Another explanation is that the lower malignant 
progression found by this study is due to the more advanced treatment modalities since all 
reports from the 20
th
 century were excluded. 
Interestingly, only one of the Turku patients with VH progressed to VC. No progression to 
SCC was reported. Since the PAD referral letters were collected from the archives of the 
Department of Oral Pathology, all prospective information on the patients with 
recurrence/progression of the disease was not available. This might explain the low number of 
malignant progression in the Turku patients. Another explanation is that based on the 
histology of biopsy samples we – as pathologists - are keen to ask the clinicians to keep the 
patients with VH in close follow-up. Thus, both the schedule of follow-up and treatment 
mode are of crucial importance. This study, however, excludes the role of treatment in the 
outcome of the lesions, since the data was available only for a minority of the patients in the 
literature review and not at all for the Turku patients. 
One major difficulty when comparing the frequency of malignant transformation of PVL or 
VH in different studies is the inclusion criteria of the patients. For example, malignancy was 
an inclusion criteria for Klanrit et al. while Fettig et al. excluded all patients, who presented 
malignancy of the oral cavity at the baseline of the follow-up (32,24). 
Field cancerization is often evident in patients with PVL progressing to carcinomas. Bagan et 
al. showed that more than 50% of the patients that developed a SCC also developed at least 
one additional primary SCC (16). Gandolfo et al. showed that 42% developed an additional 
primary tumor, and Ghazali et al. showed that 44% developed multifocal SCC (25,27). In the 
review by the Pentenero et al., the second primary tumor was reported in 37.2% of the 
patients (8). 
In the present study the majority of the patients with PVL from the literature were treated with 
surgery (67%, 138/205) and laser (32%, 64/205). Similarly, also the patients with VH were 
treated with surgery (60%, 211/352). In addition, photodynamic therapy was also used to treat 
26% (92/352) of the patients with VH. Surgery is considered the preferred treatment of PVL, 
but because of the high recurrence rate there is no consensus on the most efficient and 
effective treatment mode of PVL (67). Photodynamic therapy has been shown effective for 
VH but more studies are needed (45,47,48,58,63). 
Gathering data on PVL and VH for the systematic review in the present study was 
challenging. The major challenge was the terminology of both PVL and VH, in many cases 
most likely presenting the same course of disease. Furthermore, Mete et al suggests that PVL 
is under-diagnosed instead of over-diagnosed because there are no specific histological 
features in PVL (33). Because of this diagnostic confusion, there has recently been an attempt 
to propose clear diagnostic criteria for PVL (2, 3). Cerero-Lapiedra et al. proposed diagnostic 
criteria for PVL using a set of major and minor criteria (2). Carrard et al. simplified these 
criteria as given below (3). 
1) leukoplakia with verrucous or wartlike areas that involve more than two oral subsites 
2) at least 3 cm in size when adding all involved sites 
3) evolution of lesion through spreading, enlarging and recurrence during a recorded 
history of at least five years 
4) a biopsy has ruled out VC and SCC 
These diagnostic criteria have been retrospectively evaluated as a useful tool (68).  
One has to note that PVL is rather a clinical term of the disease entity while VH describes 
only the histology of the lesion. As already proposed by Hansen et al. in 1985, the spectrum 
of the histological findings is the major finding of the lesion of interest and VH may refer to a 
lesion that should be considered as an irreversible precursor to VC (1). All this might explain 
the confusion in the literature. Based on the present study and our experience in the field, we 
suggest that VH should be kept as a histologic diagnosis as such.  
As the histology of the PVL lesion is the most critical issue in determining the treatment and 
even outcome of the lesions, we suggest that the 4
th
 criteria in Carrard et al.’s classification 
should be more clearly defined (3). The major question is that since PVL is clinically defined 
as a verrucous lesion, should this “phenotype” be confirmed by histology. If so, the histologic 
criteria should be that of VH as classified by Pindborg et al.: VH is an exophytic overgrowth 
of well-differentiated keratinized epithelium that is similar to VC but without the destructive, 
pushing border at its interface with the underlying connective tissue (11). Thus, we now 
suggest that the 4
th
 criteria should be modified as follows: a biopsy has ruled out VC and SCC 
and confirmed the presence of VH in at least one of the possible multiple biopsies. 
By using this suggested modification, the clinicians have less difficulty in settling the 
diagnosis of PVL. Once again the close follow-up of patients clinically but also including 
biopsy sampling will result in early detection of malignant transformation either to VC or 
SCC. As long as the etiology and etiopathogenesis is not known, no disease specific treatment 
is available. Furthermore, whether there are several etiological factors causing slightly 
different PVL was not possible to determine. Maybe in the future PVLs could be categorized 
at least into three groups by etiology: 1) PVL prone to progress to verrucous carcinoma, 2) 
PVL prone to progress to squamous cell carcinoma and 3) PVL without any risk to malignant 
transformation. Also research to identify the etiologic factors of PVL is highly warranted to 
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34 L  
27 S 
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10 10 F 72 NA 10 6 8 4     NA NA NA NA 1 5 60 
Bagan et al., 
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13 13 F 68 NA 13 9 7 7  1 1  3 
S(s)/S(t) 
NA NA NA 0 8 62 
Bagan et al., 
2004; 2003 
(16,17) 
30 24 / 6 71 m 30
 
30 25* 19*  15*   7 S(s) 18 L 
24 S 
 
4.7 26 REC 
25 NL 
8 19 90* 
Campisi et al., 
2004 (18) 
58 36 / 22 67 s, 
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NA        17 S(s)  
10 A 
NA NA NA 3 22 43 
Chainani-Wu et 
al., 2013 (19) 
1 1 M 46 e    1      1 S(s) 
0 A 
1 L 12 1 DF 0 1 
 
100 
Dal Vechio et 
al., 2012 (20) 
1 1 F 76 1   1      0 1 L 
1 S 
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Del Vecchio et 
al., 2013 (21) 
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Issrani et al., 
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Chen HM et 
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****** (62) 
 
18 1 / 17 47 s, 
m 
2 11  2  3   17 S(s) 
17 S(t) 
18 P NA 18 DF 0 0 0 
 
 
F = Female, M = Male,  
s = single, m = multifocal, e = extensive 
Other = eg vestibulum, retromolar area, oral commisure 
S(s) = smoker/former smoker, S(t) = smokeless tobacco use/former use, A = any alcohol use 
L = laser, S = surgery, R = radiotheraohy, P = topical 5-aminolevulinic acid-mediated photodynamic therapy, tM = topical medication including 
methisoprinol-therapy, retinoic acid, beta-carotene, bleomycin, sM = systemic retinoids, M = medical therapy not specified, Ch = Chemotherapy, NT = no 
treatment 
REC = recurrence/(new lesion) of PVL, DF= disease free, NL = new lesions, NC = not curative 
Cis = carcinoma in situ, VC = verrucous carcinoma, SCC = squamous cell carcinoma 
 
* interpreted and/or combined data from the available data 
** median instead of mean 
*** number of lesions, not able to identify individual patients 
**** 13 patients previously reported in 47, 48, 60 
***** 5 patients previously reported in 63 
****** all patients previously reported in 45, 47, 48, 58, 60, 63 
  
Yu et al., 2008 
**** (63) 
36 1 / 35 51 s, 
m 
 24  3 1 8   35 S(s) 
35 S(t) 
36 P 2.2 36 DF 0 0 0 




51 / 70 59 NA 19 29 39 7  20 7  31 S(s) 
34 A 
121 S NA NA NA NA NA 
Table 2. Patients diagnosed with VH during the years 2000-2013 at the 
Department of Oral Pathology, Institute of Dentistry, Faculty of Medicine, 
























































































1 F 40 - NA T NA NA - - 
2a F 38 + 10 Bc NA 4.8 + Mi 
2b    10 T   - Mi 
3  M 53 + NA Lm S NA - - 
4 M 64 - NA Bc NA 1  + Mi 
5 M 62 - 10 F NA 2.1 - Mi 
6 
 
M 68 - 10 P NA NA - - 
7 I 
 
M 63 - 5 L S 0.5 - - 
7 II 
 
M 64 - NA L S 1.2 - - 





F 55 - 6 T NA 1 
 
- - 
9 F 57 - NA T S NA + Mo 
10 M 55 + NA B NOS NA - Mi 
11 F 65 - 30 T NA NA - - 
12  F 78 - 8 T NA NA + - 
13 I F 76 - 13 Bs NA 2 - - 
13 II F 76 - NA 
 
Bs NA 2.1 - Mo 
14 I a 
 
F 80 + 30 Bs NOS / 
NOA 
0.8 - - 




F 81 + NA AC NOS / 
NOA 




F 81 + 20 
 
AC NOS / 
NOA 
1.3 + Mi 
14 III 
b 
   35 B   + Mi 
14 III 
c 
   22 AC   + Mi 
14 IV 
 




1.9 - - 
14 V a 
 
F 82 + NA AC NOS / 
NOA 
2.3 - - 
14 V b    NA AC   - Mo 
15 M 60 - 8 P S NA - - 
16 F 65 - NA F NA NA - - 
17 F 60 - 10 P NA 1 + Mo 
18 F 47 - 4 T S 0.3 - - 
 
NA = data not available, + = yes, - = no 
F = female, M = male, 
T = tongue, B = buccal mucosa, Bc = buccal/oral commissure, Bs = buccal sulcus, L 
= lip, Lm = labial mucosa, F = floor of mouth, P = palate, G = gingiva, AC = alveolar 
crest, 
S = smoker / former smoker, NOS = non-smoker, NOA = no alcohol consumption, 
Mi = mild dysplasia, Mo = moderate dysplasia  
 
number plus small letter = two biopsies taken at the same time from different areas 
number plus roman number = biopsies taken at different time 
  
 
19 M 35 - 9 T NA NA - - 
20  F 75 - NA AC NA 0.5 - Mi 
21  
 
F 76 - 10 T NA 0.2 - - 
22  M 34 - NA T NA 2 - - 
23  M 70 - 5 T NA NA - - 
24 F 72 - 10 B NA NA - Mi 
25 M 49 - NA T NA 0.2 - + 
26 a F 87 + 15 
 
Lm NA NA - Mo 
26 b    10 T   - Mi 
27 F 11 + NA B NA 0.4 - - 
28 
 
F 50 + 8 F NA NA - - 




S 2 + Mo 
 
Table 3. Pooled data on PVL and VH patients from the literature and data from 
the patients diagnosed with VH at the Department of Oral Pathology, Institute of 
Dentistry, Faculty of Medicine, University of Turku, Turku, Finland. 








Total number of 
patients 
388 848 1236 29 
F/M-ratio 2.2:1 1:3.8 1:1.3 1.4:1 






(VC + SCC) 
47 % (173/366) 5 % (25/525) 22% (196/891) 3 % (1VC) 
Gingiva 59% (178/300) 10% (45/430)   31% (223/730) 7% (2/29) 
Buccal 47% (142/300) 51% (221/430)   50% (363/730) 34% (10/29) 
Tongue 44% (131/300) 13% (58/430)    26% (189/730) 48% (14/29) 
Palate 31% (92/300) 7% (31/430)  17% (123/730) 10% (3/29) 
Alveolar Crest 21% (62/300) 0.5% (2/430)   9% (64/730) 24% (7/29) 
Lip 9% (27/300) 12% (50/430)   11% (77/730) 17% (5/29) 
Floor of mouth 8% (23/300) 5% (19/430)   6% (42/730) 10% (3/29) 
Surgery 67% (138/205) 60% (211/352)  19% (65/348)  
Laser 31% (64/205) 0.6% (2/352)  19% (66/348)  
Topical 
Medication 
17% (35/205) 0% (0/352)  10% (35/348)  
Photodynamic 
therapy 
0,01% (1/205) 26% (92/352)  27% (93/348)  
* information on smoking status was not reported for all 30 patients: in addition to the 
6 patients reported to smoke, 2 patients were reported not to smoke 
 
